Top Markets
#1 Wrapped One Wrapped One +14,737.38%
#2 Wrapped STX (Velar) Wrapped STX (Velar) +2,972.21%
#3 Black Phoenix Black Phoenix +335.82%
#4 aPriori aPriori +148.53%
#5 Bedrock Bedrock +75.14%
#6 Cysic Cysic +50.00%
#7 Prom Prom +47.31%
#8 Playnance Playnance +34.96%
#9 Bitway Bitway +29.10%
#10 COTI COTI +25.76%
Coin of the day
Wrapped One Wrapped One
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Arch Therapeutics, Inc. Arch Therapeutics, Inc.

Arch Therapeutics, Inc.

ARTH
Classement en actions #42478
Arch Therapeutics, Inc., operating alongside its affiliated companies,... Arch Therapeutics, Inc., operating alongside its affiliated companies, functions as a biotechnology firm within the United States. The organization focuses on developing and commercializing products derived from its unique AC5 self-assembling technology platform. These innovations are engineered to arrest bleeding, control fluid leakage, and assist in wound care during surgical interventions, following trauma, throughout interventional medical procedures, or in cases of disease. Its leading products, the AC5 advanced wound system and the AC5 topical hemostat, are specifically designed for application on the skin, proving effective for managing intricate chronic wounds or acute surgical injuries. The company was established in 2006 and is headquartered in Framingham, Massachusetts.
Prix de l'action
$0.0009
Dernière synchronisation: 2025-05-27
Capitalisation boursière
$1.15K
Changement (1 jour)
0.00%
Changement (1 an)
0.00%
Pays
US
Échange Arch Therapeutics, Inc. (ARTH)

Catégorie

Healthcare
Bénéfices pour Arch Therapeutics, Inc. (ARTH)
Bénéfices en Jun 2024 TTM : $-12.26M
Selon les derniers rapports financiers de Arch Therapeutics, Inc., les bénéfices actuels de l'entreprise sont de $-12.26M. En 2022, l'entreprise a réalisé un bénéfice de $-5.28M, une augmentation par rapport à celui de 2021 qui était de $-6.24M. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour Arch Therapeutics, Inc. de 2011 à 2026
Bénéfices à la fin de chaque année
Année Bénéfices Changez
2026 (TTM) $-12.26M 75.61%
2023 $-6.98M 32.35%
2022 $-5.28M -15.46%
2021 $-6.24M 33.02%
2020 $-4.69M 3.16%
2019 $-4.55M -5.53%
2018 $-4.81M -38.19%
2017 $-7.79M 29.98%
2016 $-5.99M 103.30%
2015 $-2.95M -63.80%
2014 $-8.14M 339.25%
2013 $-1.85M 4,963.48%
2012 $-36.61K 626.84%
2011 $-5.04K 0.00%
Bénéfices des entreprises similaires ou concurrentes
Entreprise Bénéfices Différence de bénéfices Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -43,115.92%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -16,007.22%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -24,611.12%
BE
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR